Studies suggest Ozempic, Mounjaro may slow tumor progression, WSJ reports

New studies suggest GLP-1 drugs such as Ozempic and Mounjaro, developed by Novo Nordisk (NVO) and Eli Lilly (LLY), may significantly improve cancer outcomes by reducing tumor progression, lowering mortality risk, and potentially decreasing breast cancer incidence, adding to the growing list of health benefits associated with GLP-1 therapies, The Wall Street Journal’s Xavier Martinez reports. Observational studies showed GLP-1 users had reduced cancer spread, with lung and breast cancer progression cut by half, Martinez writes, adding that GLP-1 users were 25% less likely to be diagnosed with breast cancer and had higher five-year survival rates in other studies.